Estimating Individual Lifetime Benefit and Bleeding Ris Aspirin for Patients With Stable Cardiovascular Disease Trial

European Heart Journal

40, 3771-3778a

DOI: 10.1093/eurheartj/ehz404

Citation Report

#	Article	IF	Citations
1	Chronic Coronary Syndromes: Genetics, Shear Stress, and Biomarkers. European Heart Journal, 2019, 40, 3367-3371.	14.7	4
2	Estimating Individual Lifetime Benefit and Bleeding Risk of Adding Oral Anticoagulation to Aspirin for Patients With Stable Cardiovascular Disease: Directions From COMPASS?. European Heart Journal, 2019, 40, 3779-3781.	14.7	4
3	Between Scylla and Charybdis: Combining Anticoagulants With Platelet Inhibitors and Outcome. European Heart Journal, 2019, 40, 3737-3740.	14.7	1
4	Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease. Cardio-Oncology, 2020, 2, 400-410.	5.3	21
5	Cardiovascular Comorbidity: Patient With Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events?. Rational Pharmacotherapy in Cardiology, 2020, 16, 607-613.	0.6	5
6	Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD. Drugs, 2020, 80, 1465-1475.	15.5	13
7	Dual Pathway Inhibition for Vascular Protection in Patients With Atherosclerotic Disease: Rationale and Review of the Evidence. Thrombosis and Haemostasis, 2020, 120, 1147-1158.	4.6	32
8	Frontiers of Acute Coronary Syndromes: Primary PCI Time Window, 15-Year Outcomes, Bleeding and MINOCA. European Heart Journal, 2020, 41, 805-809.	14.7	3
9	Predicting 10-Year Risk of Recurrent Cardiovascular Events Andcardiovascular Interventions in Patients With Established Cardiovascular Disease: Results From UCC-SMART and REACH. International Journal of Cardiology, 2021, 325, 140-148.	3.2	23
10	Cardiovascular Risk Prediction Tools Made Relevant for GPs and Patients. Heart, 2021, 107, 332-340.	4.9	7
11	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. Journal of the American College of Cardiology, 2021, 77, 511-525.	12.0	17
12	Selección de lo mejor del año 2020 sobre el tratamiento antitrombótico para el cardiólogo clínico. REC: CardioClinics, 2021, 56, 54-58.	0.3	0
13	Added Value of Cardiovascular Calcifications for Prediction of Recurrent Cardiovascular Events and Cardiovascular Interventions in Patients With Established Cardiovascular Disease. International Journal of Cardiovascular Imaging, 2021, 37, 2051-2061.	1.9	9
14	Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The Role of the COMPASS Strategy. Current Cardiology Reviews, 2021, 17, 294-305.	2.9	4
15	Use of Antithrombotic Therapy for Secondary Prevention in Patients With Stable Atherosclerotic Cardiovascular Disease: Insights From the COordinated National Network to Engage Cardiologists in the Antithrombotic Treatment of Patients With CardioVascular Disease (CONNECT-CVD) Study. International Journal of Clinical Practice, 2021, 75, e14597.	2.0	2
16	Antithrombotic Therapies in Aortic and Peripheral Arterial Diseases in 2021: A Consensus Document From the ESC Working Group on Aorta and Peripheral Vascular Diseases, the ESC Working Group on Thrombosis, and the ESC Working Group on Cardiovascular Pharmacotherapy. European Heart Journal, 2021, 42, 4013-4024.	14.7	135
17	Risk Stratification in Patients With Ischemic Stroke and Residual Cardiovascular Risk With Current Secondary Prevention. Clinical Epidemiology, 2021, 13, 813-823.	3.9	12
18	Optimisation of Oral Anticoagulants for Patients With Atrial Fibrillation Within 12 Months After Percutaneous Coronary Intervention: A Meta-Analysis and Systematic Review. IJC Heart and Vasculature, 2021, 36, 100850.	2.6	3

#	Article	IF	Citations
19	Prolongation of Disease-Free Life: When Is the Benefit Sufficient to Warrant the Effort of Taking a Preventive Medicine?. Preventive Medicine, 2022, 154, 106867.	3.3	1
20	Coronary Artery Disease With a High Risk of Complications: How to Identify Such Patients and Choose Management Tactics?. Rational Pharmacotherapy in Cardiology, 2020, 16, 465-473.	0.6	0
21	Clinical Implications of the Log Linear Association Between LDL-C Lowering and Cardiovascular Risk Reduction: Greatest Benefits When LDL-C >100 mg/Dl. PLoS ONE, 2020, 15, e0240166.	3.2	8
22	Dual Pathway Inhibition in Atherothrombosis Prevention: Yes, Now We Can!. Minerva Cardiology and Angiology, 2023, 71, 363-373.	1.3	2
23	Dual Pathway of Inhibition and Vascular Protection in Patients With Atherosclerotic Disease. , 2021, .		0
24	Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk. Diabetes Care, 2022, 45, 1211-1218.	20.9	15
25	Clinical Experience With Dual Pathway Inhibition Therapy: Case Series and Mini Review. European Heart Journal - Case Reports, 2022, 6, ytac201.	0.6	1
26	Кровотечение из варикозно расширеннных вен мошонки на терапии ривароксабаном как индикатор проблемы у пожилого пациента: клинический случай. Kuban Scientific Medical Bulletin, 2022, 29, 89-102.	0.5	0
27	Acute, Periprocedural and Longterm Antithrombotic Therapy in Older Adults: 2022 Update by the ESC Working Group on Thrombosis. European Heart Journal, 2023, 44, 262-279.	14.7	58
28	Recurrent Venous Thromboembolism and Bleeding With Extended Anticoagulation: The VTE-PREDICT Risk Score. European Heart Journal, 2023, 44, 1231-1244.	14.7	84
29	Bleeding Risk in Patients With Peripheral Arterial Disease. Life, 2023, 13, 47.	4.3	10
30	External Validation of Bleeding Risk Models for the Prediction of Long-Term Bleeding Risk in Patients With Established Cardiovascular Disease. American Heart Journal, 2023, 260, 72-81.	3.3	9
31	Residual Cardiovascular Risk: When Should We Treat It?. European Journal of Internal Medicine, 2024, 120, 17-24.	4.2	83
32	Effect of Intermittent Pneumatic Compression on Preventing Deep Vein Thrombosis Using Microfluidic Vein Chip. Frontiers in Bioengineering and Biotechnology, 2023, 11, 1281503.	5.8	8
33	Generalisability of Trials on Antithrombotic Treatment Intensification in Patients With Cardiovascular Disease. Heart, 2024, 110, 482-490.	4.9	4
34	Net Clinical Benefit of Extended Dual Pathway Inhibition According to Baseline Risk in Patients With Chronic Coronary Syndrome: A COMPASS Substudy. European Heart Journal - Cardiovascular Pharmacotherapy, 2024, 10, 201-209.	5.0	4
35	Risk Stratification of Net Adverse Clinical Events Using CHADS-P2A2RC and CHADS2 Scores in Chronic Coronary Syndrome Patients Without Atrial Fibrillation: Insights From the CLIDAS-PCI. International Journal of Cardiology, 2025, 437, 133464.	3.2	3